Data-independent Proteomic Screen Identifies Novel Tamoxifen Agonist That Mediates Drug Resistance

Overview

Journal J Proteome Res

Publisher American Chemical Society

Specialty Biochemistry

Date 2011 Sep 23

PMID 21936522

Citations 26

Authors

Shawna Mae Hengel

Euan Murray

Simon Langdon

Larry Hayward

Jean ODonoghue

Alexandre Panchaud

Ted Hupp

David R Goodlett

Affiliations

Soon will be listed here.

Abstract

A label-free quantitative variation of the recently developed data-independent shotgun proteomic method precursor acquisition independent from ion count (PAcIFIC) was used to identify novel proteins implicated in cancer progression and resistance. Specifically, this screen identified the pro-metastatic protein anterior gradient 2 (AGR2) as significantly up-regulated in tamoxifen-treated cells. Highlighting the need for direct proteome profiling methods like PAcIFIC, neither data-dependent gas-phase fractionation nor a transcriptomic screen detected AGR2 protein/transcript at significantly up-regulated levels. Further cell-based experiments using human cancer cell lines and in vivo xenografts confirmed the PAcIFIC hypothesis that AGR2 is up-regulated in MCF-7 cells post tamoxifen treatment and that it is implicated in drug resistance mediation.

Citing Articles

AGR2 knockdown induces ER stress and mitochondria fission to facilitate pancreatic cancer cell death.

Salu P, Tuvin D, Reindl K Biochim Biophys Acta Mol Cell Res. 2024; 1872(1):119854.

PMID: 39353469 PMC: 11608140. DOI: 10.1016/j.bbamcr.2024.119854.

AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer.

Zhang K, Li Y, Kong X, Lei C, Yang H, Wang N Front Oncol. 2023; 13:1195885.

PMID: 37197416 PMC: 10183570. DOI: 10.3389/fonc.2023.1195885.

From development to cancer - an ever-increasing role of AGR2.

Jach D, Cheng Y, Prica F, Dumartin L, Crnogorac-Jurcevic T Am J Cancer Res. 2021; 11(11):5249-5262.

PMID: 34873459 PMC: 8640830.

Nuclear Mechanisms Involved in Endocrine Resistance.

Dittmer J Front Oncol. 2021; 11:736597.

PMID: 34604071 PMC: 8480308. DOI: 10.3389/fonc.2021.736597.

Quantitative shotgun proteome analysis by direct infusion.

Meyer J, Niemi N, Pagliarini D, Coon J Nat Methods. 2020; 17(12):1222-1228.

PMID: 33230323 PMC: 8009190. DOI: 10.1038/s41592-020-00999-z.

References

Nie L, Wu G, Zhang W . Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. Biochem Biophys Res Commun. 2005; 339(2):603-10. DOI: 10.1016/j.bbrc.2005.11.055. View

Toffanin S, Daidone M, Miodini P, De Cecco L, Gandellini P, Cappelletti V . Clusterin: a potential target for improving response to antiestrogens. Int J Oncol. 2008; 33(4):791-8. View

Shaffer S, Prior D, Anderson G, Udseth H, Smith R . An ion funnel interface for improved ion focusing and sensitivity using electrospray ionization mass spectrometry. Anal Chem. 1998; 70(19):4111-9. DOI: 10.1021/ac9802170. View

Cory A, Owen T, BARLTROP J, CORY J . Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991; 3(7):207-12. DOI: 10.3727/095535491820873191. View

Barraclough D, Platt-Higgins A, de Silva Rudland S, Barraclough R, Winstanley J, West C . The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol. 2009; 175(5):1848-57. PMC: 2774050. DOI: 10.2353/ajpath.2009.090246. View

Stratton M, Campbell P, Futreal P . The cancer genome. Nature. 2009; 458(7239):719-24. PMC: 2821689. DOI: 10.1038/nature07943. View

Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, Domon B . High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods. 2009; 7(1):43-6. DOI: 10.1038/nmeth.1408. View

Neubauer H, Clare S, Kurek R, Fehm T, Wallwiener D, Sotlar K . Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection. Electrophoresis. 2006; 27(9):1840-52. DOI: 10.1002/elps.200500739. View

Clarke R, Liu M, Bouker K, Gu Z, Lee R, Zhu Y . Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003; 22(47):7316-39. DOI: 10.1038/sj.onc.1206937. View

10.

Shaffer S, Tolmachev A, Prior D, Anderson G, Udseth H, Smith R . Characterization of an improved electrodynamic ion funnel interface for electrospray ionization mass spectrometry. Anal Chem. 1999; 71(15):2957-64. DOI: 10.1021/ac990346w. View

11.

Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E . Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 2005; 65(15):6789-800. DOI: 10.1158/0008-5472.CAN-04-2684. View

12.

Panchaud A, Jung S, Shaffer S, Aitchison J, Goodlett D . Faster, quantitative, and accurate precursor acquisition independent from ion count. Anal Chem. 2011; 83(6):2250-7. PMC: 3217585. DOI: 10.1021/ac103079q. View

13.

Umar A, Kang H, Timmermans A, Look M, Meijer-Van Gelder M, den Bakker M . Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics. 2009; 8(6):1278-94. PMC: 2690491. DOI: 10.1074/mcp.M800493-MCP200. View

14.

Sewell J, Macleod K, Ritchie A, Smyth J, Langdon S . Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br J Cancer. 2002; 86(3):456-62. PMC: 2375224. DOI: 10.1038/sj.bjc.6600058. View

15.

Ryu S, Gallis B, Goo Y, Shaffer S, Radulovic D, Goodlett D . Comparison of a label-free quantitative proteomic method based on peptide ion current area to the isotope coded affinity tag method. Cancer Inform. 2009; 6:243-55. PMC: 2623286. DOI: 10.4137/cin.s385. View

16.

Massarweh S, Schiff R . Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2007; 13 Suppl 1:S15-24. DOI: 10.1677/erc.1.01273. View

17.

Choe L, Aggarwal K, Franck Z, Lee K . A comparison of the consistency of proteome quantitation using two-dimensional electrophoresis and shotgun isobaric tagging in Escherichia coli cells. Electrophoresis. 2005; 26(12):2437-49. DOI: 10.1002/elps.200410336. View

18.

Wang Y, He Q, Chen H, Chiu J . Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: proteomic characterization. Exp Cell Res. 2006; 313(2):357-68. DOI: 10.1016/j.yexcr.2006.10.016. View

19.

Chen G, Gharib T, Huang C, Taylor J, Misek D, Kardia S . Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002; 1(4):304-13. DOI: 10.1074/mcp.m200008-mcp200. View

20.

Redondo M, Tellez T, Roldan M, Serrano A, Garcia-Aranda M, Gleave M . Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Breast Cancer Res. 2007; 9(6):R86. PMC: 2246189. DOI: 10.1186/bcr1835. View